Applied Therapeutics Shares Slide on Lead Candidate Delay
04 January 2022 - 2:48AM
Dow Jones News
By Colin Kellaher
Applied Therapeutics Inc. shares tumbled more than 25% in early
trading Monday after the biopharmaceutical company reported further
delays in its effort to seek U.S. Food and Drug Administration
approval of its lead product candidate.
The New York company, which had been aiming to file its new drug
application for AT-007 in the rare inherited disorder galactosemia
by the end of last year, said it has put those plans on hold after
the agency indicated that clinical outcomes data from an ongoing
Phase 3 study will likely be required for approval.
Applied Therapeutics said it had previously been discussing the
galactosemia program with the FDA in the context of the agency's
accelerated approval program, which allows the use of surrogate
endpoint and can considerably shorten the time required prior to
receiving FDA approval for drugs that treat serious conditions and
fill an unmet medical need.
The company said clinical outcomes in the Phase 3 study of
AT-007 are assessed every six months, with the first assessment
slated for completion in the first quarter. The assessments will
continue every six months until the study reaches statistical
significance.
Applied Therapeutics, which last year pushed its planned filing
from the third quarter to the fourth quarter due to changes in the
study, Monday said it was "disappointed by this change in direction
by the FDA," and that it would work with the agency to determine
the most expeditious path forward to approval of the drug.
There are currently no drugs approved for galactosemia, which
hinders the body's ability to process and produce energy from a
sugar called galactose.
Applied Therapeutics shares were recently changing hands at
$6.65, down 25.7%, after hitting a 52-week low of $6 early in the
session. The stock is more than 75% below the 52-week high of
$29.80 it reached last February.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 03, 2022 10:33 ET (15:33 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Applied Therapeutics (NASDAQ:APLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Therapeutics (NASDAQ:APLT)
Historical Stock Chart
From Apr 2023 to Apr 2024